Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting androgen-driven resistance to immune checkpoint inhibitors in pancreatic ductal adenocarcinoma

Award Number: R21CA307819
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/06/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Targeting androgen-driven resistance to immune checkpoint inhibitors in pancreatic ductal adenocarcinoma - Project summary Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and striking sex-based differences in immune responses. Despite the transformative impact of immune checkpoint inhibitors (ICI) in oncology, their efficacy in PDAC is notably poor. Our research reveals that the vasoactive intestinal polypeptide (VIP) receptor (VPAC) acts as a novel immune checkpoint that suppresses macrophage phagocytosis and adaptive anti-tumor immunity. Notably, VPAC blockade enhances macrophage-mediated tumor control in female PDAC models, but not in males. Whereas androgen signaling suppresses macrophage-mediated immunity in males. Androgen receptor blockade overcomes this and sensitizes VPAC antagonist response in male PDAC models. Building on these insights, we propose a sex- specific approach to reinvigorate the PDAC immune microenvironment by targeting VIP receptor 1 (VPAC1) in females and combining androgen receptor (AR) inhibition with VPAC blockade in males. Thus, our central hypothesis is that activating macrophage phagocytosis by targeting immune checkpoints or androgen receptor (AR) promotes an immune-permissive TME, enhances ICI responses and suppresses PDAC progression. We aim to: Aim 1: Define the sex-specific differences in macrophages regulating anti-tumor immunity against PDAC. We will elucidate how VPAC1 in females and AR/VPAC1 cooperation in males contribute to PDAC immune evasion. By leveraging multiplex fluorescence microscopy, single-cell RNA sequencing (scRNAseq), and functional assays, we will characterize macrophage-T cell interactions and assess the impact of VPAC1 and AR inhibition on tumor immunity. Aim 2: Enhance anti-tumor immune responses by combining VPAC blockade with macrophage- checkpoint inhibitors. We will evaluate the therapeutic potential of combining VPAC1/PD-1 blockade with TIM3 inhibition to amplify macrophage-mediated anti-tumor immunity in both sexes. Our murine PDAC models and mechanistic studies will determine the efficacy and underlying mechanisms of this approach. This project is highly innovative, introducing VPAC1 as a novel macrophage phagocytosis checkpoint and defining its role in sex-specific immunosuppression. Our strategy holds significant translational potential to inform precision immunotherapy and advance clinical interventions for PDAC patients. By addressing the profound sex disparities in immune response, our findings could reshape immunotherapeutic paradigms and improve survival outcomes for both male and female PDAC patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $402,401 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	1	4/6/2026	NEW	$402,401
														Subtotal = $402,401

Grand Total All Awards = $402,401

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting androgen-driven resistance to immune checkpoint inhibitors in pancreatic ductal adenocarcinoma

Award Number: R21CA307819

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/06/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer